Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Abstract: The COVID-19 pandemic has forced us to reconsider the relationship between public and private research and development (R&D). The policy issue is whether, over the next 20 years, governments’ only negotiating position on biomedical technologies will be to sign one purchase contract after another and transfer value from tax payers to investors in pharmaceutical companies. Knowledge and technologies that are crucial to Covid-19 vaccine development and production were created with the contribution of governments. Patents filed by pharma companies do not protect the public interest arising from such earlier research. The paper offers a case study on the privatization of knowledge created in the first place by R&D in the public sector or supported by public funds and eventually being appropriated by pharmaceutical corporations.

Vaccins contre la Covid-19 --- Recherche industrielle --- Investissements publics --- Industrie pharmaceutique. --- États-Unis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Le docteur Philippe Casassus est professeur émérite de Thérapeutique à l'Université Sorbonne-Paris Cité. En tant que rédacteur en chef adjoint de la revue Médecine, il a suivi régulièrement les publications scientifiques de la presse médicale pour en faire des synthèses pour ses confrères. Il s'est donné l'objectif ici d'en tirer les principales leçons pour le public non médical, tout en gardant le principe de référencer précisément les données résumées ici

COVID-19 --- COVID-19 Vaccines --- SARS-CoV-2 --- Severe Acute Respiratory Syndrome --- Covid-19. --- SARS-CoV-2 (virus). --- Syndrome respiratoire aigu sévère --- Vaccins contre la Covid-19 --- COVID-19 Pandemic, 2020 --- -COVID-19 (Disease) --- Vaccination. --- Virus du SRAS. --- Syndrome respiratoire aigu sévère. --- Covid-19 --- SARS-CoV-2 (virus) --- SARS-CoV-2. --- Syndrome respiratoire aigu sévère --- COVID-19.